Peptides vs Steroids: How They Differ

Peptides are often sold as the safe, legal alternative to steroids. They are chemically different and they work differently, but "safer" is not a finding anyone has established. Here is what the research actually compares, and where it has nothing to compare.

Short answer: anabolic steroids are testosterone and its derivatives. They bind the androgen receptor and switch on muscle-building genes directly, and decades of data show both that they work and how they cause harm^1,3. The "peptides" used for physique goals are mostly signalling molecules, such as growth hormone releasing hormone (GHRH) analogues, growth hormone secretagogues (GHS), and healing peptides like BPC-157. They act on cell-surface receptors and usually push the body to release more of its own hormones⁶. Their effects are generally smaller and far less well measured, and for most of them no long-term human safety data exist^6,9. So "peptides are safer than steroids" cannot be confirmed. The comparison has mostly not been studied.

This guide compares the two groups on mechanism, evidence, side effects and legal status. It adds a broader comparison to the brief one in are peptides safe? It is educational only, not medical advice.

Peptides vs steroids at a glance

Definitions: what counts as a steroid and what counts as a peptide

Anabolic-androgenic steroids are testosterone and molecules derived from it. The 2026 WADA Prohibited List gives a long list of examples, including testosterone, nandrolone, oxandrolone, stanozolol, trenbolone and boldenone, as well as "other substances with a similar chemical structure or similar biological effect(s) including their esters"¹⁵. Testosterone used in medical replacement therapy is the same molecule. The difference is the dose and the purpose. Where TRT fits against a non-steroid option is covered in TRT vs enclomiphene.

Peptides are short chains of amino acids. The name covers very different things. Some are FDA-approved medicines, such as the GLP-1 drugs, and tesamorelin, a GHRH analogue approved to reduce excess abdominal fat in HIV-associated lipodystrophy⁸. Others are experimental. In physique and anti-ageing settings, "peptides" usually means GHRH analogues (CJC-1295, sermorelin, tesamorelin), growth hormone releasing peptides and secretagogues (ipamorelin, GHRP-2, GHRP-6, hexarelin), and "recovery" peptides like BPC-157 and TB-500. Two edge cases are worth knowing. Ibutamoren (MK-677) is often grouped with these peptides but is an orally active small molecule, not a peptide⁶. Growth hormone itself is a protein hormone, and WADA lists it in the same S2 class as the peptides¹⁵.

Mechanisms: nuclear receptor vs cell-surface signal

Steroids are fat-soluble and cross into cells. The Endocrine Society's scientific statement describes it this way: once testosterone binds its androgen receptor, the complex "translocates into the nucleus", where it regulates gene expression¹. That direct route is why exogenous testosterone builds muscle whatever the body's own hormone output is. In a randomized trial of 43 healthy men, 600 mg of testosterone enanthate a week for 10 weeks increased fat-free mass, muscle size and strength even without exercise. Combined with weight training, fat-free mass rose by an average of 6.1 kg³.

GH-axis peptides act further upstream. GHRH analogues bind the GHRH receptor, a G-protein-coupled receptor in the pituitary. Growth hormone releasing peptides and secretagogues bind a different receptor (GHS-R) and act on both the pituitary and the hypothalamus⁶. Either way, the peptide asks the pituitary to release growth hormone, and the body's feedback loops stay active. A review of secretagogues concludes that they "promote pulsatile release of GH that is subject to negative feedback and can prevent supra-therapeutic levels of GH"⁶. That built-in limit is a real pharmacological difference from injecting a hormone directly. It also means the effect is smaller and depends on how responsive the person's pituitary is.

For BPC-157, TB-500 and most other recovery peptides, the proposed mechanisms (growth of new blood vessels, growth-factor signalling) come mainly from animal and cell studies. See the BPC-157 page for the evidence.

Evidence tiers: why the comparison is uneven

The two groups have not been studied to anything like the same depth, and that gap is the most important point on this page.

1. Anabolic steroids have randomized trials showing they work³, and large observational research on harms in people using them outside medicine. An estimated 2.9–4.0 million Americans aged 13–50 have used AAS⁴. The Endocrine Society notes that randomized trials "cannot ethically duplicate" the doses users take, so much of the harm data is observational¹.
2. Growth hormone has randomized trials. A systematic review of 18 study populations of healthy older adults found about 2 kg more lean mass, about 2 kg less fat mass, and no change in body weight. It concluded GH "cannot be recommended as an anti-aging therapy"⁵.
3. GH secretagogues have a handful of controlled trials. The largest well-known one tested ibutamoren (not a peptide) in 65 older adults for up to 2 years and found 1.1 kg more fat-free mass than placebo at 12 months⁷. A 2018 review found few long-term, rigorously controlled studies⁶.
4. BPC-157, TB-500 and similar have essentially no published controlled human outcome trials. FDA's compounding safety review lists "no human exposure data" for TB-500, KPV and MOTS-c, and "inadequate safety information" for BPC-157 by its proposed routes⁹.

Side-effect profiles from the sources

Anabolic-androgenic steroids

The Endocrine Society statement links performance-enhancing drug use to a higher risk of death and to cardiovascular, psychiatric, metabolic, endocrine, hepatic, renal and musculoskeletal disorders¹. The best-documented AAS effects:

1. Hormone shutdown. After months or more of use, the body's own testosterone axis "may be suppressed for months, or years; and some individuals may never regain normal testosterone levels"¹.
2. Reproductive and cosmetic effects: infertility, gynecomastia, sexual dysfunction, hair loss, acne and testicular atrophy¹.
3. Heart. In 140 experienced male weightlifters, long-term AAS users had lower left-ventricular ejection fraction than non-users (52% vs 63%) and more coronary plaque. Plaque increased with cumulative years of use².
4. Liver. "Virtually all" AAS-related liver toxicity comes from oral 17α-alkylated steroids¹.
5. Mind and dependence. Some users have hypomanic or manic symptoms while on AAS and depressive symptoms during withdrawal, including occasional suicidality. An estimated 32.5% of users develop AAS dependence¹.

Growth hormone and GH-axis peptides

In the trials of GH in healthy older adults, treated participants were significantly more likely to have soft-tissue swelling, joint pain, carpal tunnel syndrome and gynecomastia. They were also somewhat more likely to develop diabetes or impaired fasting glucose⁵. The Endocrine Society lists similar effects in people misusing GH: oedema, excessive sweating, muscle and joint pain, carpal tunnel syndrome and diabetes¹. Secretagogues produce a milder version of the same pattern. The 2018 review reports that they are generally well tolerated but that raised IGF-1 on these drugs "lead[s] to increased insulin insensitivity, which can result in blood glucose elevations"⁶. In the ibutamoren trial, fasting glucose rose by an average of 5 mg/dL, insulin sensitivity fell, and the most common side effects were increased appetite, mild leg swelling and muscle pain⁷.

The compounded or "research" versions add a separate risk: what is actually in the vial. FDA's review cites immunogenicity and impurity risks for GHRP-2, GHRP-6 and ipamorelin, and reports of serious adverse events for some of them⁹. For CJC-1295 it cites "serious adverse events associated with increased heart rate and systemic vasodilatory reaction"⁹. Those concerns are about the products, not only the molecules. See ipamorelin and CJC-1295 for compound-level detail.

Legal status

In the US, anabolic steroids are Schedule III controlled substances¹⁰. Most GH-axis and recovery peptides are not controlled substances. They are unapproved drugs, so the issue is drug approval and compounding law rather than drug-scheduling law. Growth hormone is the exception: distributing it for non-approved uses is a federal crime with up to 5 years in prison¹¹. In the UK, anabolic steroids, somatropin and HCG are Class C drugs. The government's guidance says possessing anabolic steroids for personal use is not an offence, while supply carries up to 14 years^12,13. Australia's June 2026 Poisons Standard puts anabolic steroidal agents and many peptides (BPC-157, TB-500, CJC-1295, ipamorelin, GHRPs) in Schedule 4 and makes possessing them without authority illegal¹⁴. For more detail, see are peptides legal?

In sport, the answer is simpler. The 2026 WADA List bans anabolic agents under S1, growth hormone, GHRH analogues, secretagogues, GHRPs and TB-500 under S2, and unapproved substances including BPC-157 under S0. All three categories are banned at all times¹⁵. Switching from steroids to peptides does not make an athlete compliant.

Why "peptides are safer than steroids" is not established

The claim sounds reasonable, because GH-axis peptides keep the body's feedback control and generally produce smaller hormonal changes. But three problems stand in the way of calling them safer.

1. Nobody has compared them. We found no trial or cohort study directly comparing long-term outcomes of peptide use and steroid use.
2. The data are unequal. Steroid harms are known because millions have used them and researchers have studied those users^1,4. For peptides such as TB-500, FDA lists no human exposure data⁹. Having no evidence of harm is not evidence of safety.
3. "Peptide" is not one thing. Tesamorelin is an approved drug with a label⁸. A grey-market vial of CJC-1295 is a different product with different risks, and GH itself has documented metabolic effects⁵. One verdict can't cover all of them.

The most the sources support is narrower. GH-axis peptides act through the body's own control systems and produce smaller, feedback-limited hormone increases than injected hormones. Their measured side effects in short trials are mainly metabolic and fluid-related, and their long-term safety is unknown^6,7.

FAQ

References

Primary sources — PubMed / NEJM / The Lancet.

1. Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341-375. https://pmc.ncbi.nlm.nih.gov/articles/PMC4026349/
2. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, Pope HG Jr. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017;135(21):1991-2002. https://pmc.ncbi.nlm.nih.gov/articles/PMC5614517/
3. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1-7. https://pubmed.ncbi.nlm.nih.gov/8637535/
4. Pope HG Jr, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict. 2014;23(4):371-377. https://pmc.ncbi.nlm.nih.gov/articles/PMC3961570/
5. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. https://pubmed.ncbi.nlm.nih.gov/17227934/
6. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. https://pmc.ncbi.nlm.nih.gov/articles/PMC5632578/
7. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. https://pmc.ncbi.nlm.nih.gov/articles/PMC2757071/
8. U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin for injection) — Full Prescribing Information. accessdata.fda.gov. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
9. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
10. 21 CFR § 1308.13 — Schedule III (paragraph (f): anabolic steroids). Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/cfr/text/21/1308.13
11. 21 U.S.C. § 333(e) — Penalties: prohibited distribution of human growth hormone. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/333
12. Misuse of Drugs Act 1971, Schedule 2 (Controlled drugs), Part III: Class C drugs. legislation.gov.uk. https://www.legislation.gov.uk/ukpga/1971/38/schedule/2
13. GOV.UK. Drugs penalties. https://www.gov.uk/penalties-drug-possession-dealing
14. Australian Government Department of Health, Disability and Ageing. Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, Schedule 4 and Appendix D clause 5. Federal Register of Legislation, F2026L00633. https://www.legislation.gov.au/F2026L00633/asmade
15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026 (in force January 1, 2026) — S0, S1 and S2. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf